Back to top

AstraZeneca’s ARG iNAUT IPF Trial Puts New Respiratory Bet on Investors’ Radar

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new mid stage trial, “A Phase IIb Study to Evaluate th...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)